Bryan Vinik, MD
Endocrinology · Boca Raton, FLNPI 1649384157
Payments from drug & device makers
Across 488 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$947
- Novo Nordisk$860
- Amgen$723
- Corcept Therapeutics$502
- plus $4K from 36 others
What the payments were for
- Speaking & faculty fees$4,30033%
- Food & beverage$8,70467%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $5,074 |
| Lilly USA, LLC | 83 | $1,343 |
| Sanofi-aventis U.S. LLC | 50 | $947 |
| Novo Nordisk | 71 | $860 |
| Amgen(2 entities) | 39 | $723 |
| Corcept Therapeutics | 25 | $502 |
| Insulet Corporation | 18 | $441 |
| Bayer | 18 | $417 |
| AstraZeneca | 15 | $266 |
| Amneal Pharmaceuticals LLC | 16 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $247 |
| Xeris Pharmaceuticals, Inc. | 12 | $229 |
| Mannkind Corporation | 11 | $204 |
| Boehringer Ingelheim | 11 | $187 |
| Recordati_rare_diseases_inc. | 8 | $158 |
| Novartis | 8 | $130 |
| Merck | 7 | $115 |
| Lifescan, Inc. | 6 | $95 |
| BD | 3 | $70 |
| IBSA Pharma Inc. | 3 | $60 |
| Radius Health, Inc. | 3 | $59 |
| Nevro Corp. | 2 | $58 |
| Avvisto Therapeutics, LLC | 3 | $49 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Verity Pharmaceuticals Inc. | 2 | $47 |
| Valeritas, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $46 |
| EUSA Pharma (US) LLC | 2 | $42 |
| Dexcom, Inc. | 2 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Shire North American Group Inc | 1 | $27 |
| Sandoz | 1 | $23 |
| Pfizer | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| GRT US Holding, Inc. | 1 | $20 |
| Alvogen Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Senseonics, Incorporated | 1 | $13 |
| Linus Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$3,644
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 12 | $495,757 |
| MounjaroTirzepatide | 377 | $474,608 |
| OzempicSemaglutide | 203 | $253,084 |
| JardianceEmpagliflozin | 144 | $201,609 |
| TrulicityDulaglutide | 118 | $156,875 |
| FarxigaDapagliflozin Propanediol | 46 | $61,580 |
| Repatha SureclickEvolocumab | 43 | $50,660 |
| JanuviaSitagliptin Phosphate | 32 | $39,149 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $33,879 |
| SynthroidLevothyroxine Sodium | 261 | $33,237 |
| TradjentaLinagliptin | 22 | $33,237 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $26,316 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $25,707 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $18,480 |
| EliquisApixaban | 11 | $17,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,343 | $638,543532 claims |
| Corcept TherapeuticsKorlym | $502 | $495,75712 claims |
| Novo NordiskOzempic | $860 | $253,084203 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr | $187 | $250,556189 claims |
| AstraZenecaFarxiga | $266 | $61,58046 claims |
| MerckJanuvia, Janumet Xr | $115 | $45,78744 claims |
| AbbVieSynthroid, Armour Thyroid | $5,074 | $34,935278 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $947 | $33,87928 claims |
| PfizerEliquis | $22 | $17,08711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $255 | $4,980353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Boca Raton
- Renee FreedmanBoca Raton$10K
- Rolando RodriguezBoca Raton$8K
- Kathryn JonesBoca Raton$142
- Rodolfo Perez LopezHialeah$10.6M
- Vivian RoseCoral Springs$214K
- Carlos ZapataTallahassee$5K
- Michael FiliMiami$4K
- Mohammad BaigTampa$2K
- Myat MyintHudson$182
- Alan BalsamDeerfield Beach$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.